We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

The Place of Methyldopa in the Treatment of Severe Hypertension

James Conway, MD, PhD; Andrew J. Zweifler, MD; Stevo Julius, MD
JAMA. 1963;186(3):266-268. doi:10.1001/jama.1963.63710030042021d.
Text Size: A A A
Published online


THE MOST POTENT antihypertensive agents presently available are those which interfere with function of the sympathetic nervous system. Methyldopa (the levo isomer of alphamethyldopa), which is an effective decarboxylase inhibitor, diminishes the formation of catecholamines by inhibiting the conversion of dihydroxyphenylalanine (dopa) to dopamine.1 Although it is not known whether the fall in blood pressure produced by this drug depends upon interference with sympathetic function, its antihypertensive effects are similar to those of other autonomic blocking agents.2,3 It has been shown to be effective in the treatment of hypertension and reasonably free from side effects, and others have emphasized that it has a favorable effect on the recumbent blood pressure.4-7

Since effective drugs of this type are presently available, the place of methyldopa in the treatment of hypertension will be determined by its ability to overcome the deficiencies in the other autonomic blocking agents, notably guanethidine sulfate.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.